SCHEMBL8167328

SCHEMBL8167328

CC(C)c1ccc(Cn2c(C(=O)NCc3ccc(Cl)cc3)c(CC(=O)O)c3ccccc32)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 4/20 0.52
KMT2A Q03164 4/20 0.52
RAB9A P51151 1/20 0.52
SMN1; SMN2 Q16637 1/20 0.52
PTGER4 P35408 3/20 0.51
S1PR3 Q99500 1/20 0.48
THRA P10827 1/20 0.48
THRB P10828 1/20 0.48
FOLH1 Q04609 1/20 0.47
PPARG P37231 1/20 0.47
KDM4E B2RXH2 1/20 0.47
USP2 O75604 1/20 0.47
ALDH1A1 P00352 1/20 0.47
LMNA P02545 1/20 0.47
POLB P06746 1/20 0.47
PTGDR2 Q9Y5Y4 2/20 0.46
PTGES O14684 1/20 0.45
ALOX5 P09917 1/20 0.45
GFER P55789 1/20 0.45
PTGES2 Q9H7Z7 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8179717 0.92 PTGER4 (0.49) MEN1KMT2APTGER4S1PR3THRA
SCHEMBL4261606 0.91 S1PR3 (0.52) PTGER4S1PR3THRATHRBFOLH1
SCHEMBL13952371 0.91 PTGER4 (0.48) MEN1KMT2ARAB9ASMN1; SMN2PTGER4
SCHEMBL8175838 0.90 PTGER4 (0.47) MEN1KMT2ARAB9ASMN1; SMN2PTGER4
SCHEMBL8165192 0.89 MEN1 (0.53) MEN1KMT2ATHRATHRBFOLH1
SCHEMBL8178100 0.89 PTGDR2 (0.51) MEN1KMT2ASMN1; SMN2PTGER4THRA
SCHEMBL8180889 0.89 S1PR3 (0.47) KMT2APTGER4S1PR3THRATHRB
SCHEMBL8175849 0.87 PTGER4 (0.49) RAB9ASMN1; SMN2PTGER4S1PR3THRA
SCHEMBL8167666 0.87 POLB (0.58) PTGER4S1PR3THRATHRBFOLH1
SCHEMBL13931389 0.86 PLA2G2A (0.49) PTGER4S1PR3THRATHRBFOLH1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090047246-A1 NOVEL INHIBITORS OF HEPATITIS C VIRUS REPLICATION INTERMUNE, INC. (US) 2009-02-19 US disclosed
US-20090047246-A1 NOVEL INHIBITORS OF HEPATITIS C VIRUS REPLICATION INTERMUNE, INC. (US) 2009-02-19 US disclosed
WO-2008100867-A2 NOVEL INHIBITORS HEPATITIS C VIRUS REPLICATION INTERMUNE, INC. (US) 2008-08-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090047246-A1 NOVEL INHIBITORS OF HEPATITIS C VIRUS REPLICATION EIF2AK2, HAVCR2, HCCS MEN1 4749/4885KMT2A 2701/4885RAB9A 2895/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.